Bibliographic citations
Olascuaga, K., (2022). Proteínas asociadas a vesículas extracelulares tumorales como biomarcadores potenciales en el diagnóstico, progresión y supervivencia en diferentes tipos de cáncer [Universidad Nacional de Trujillo]. https://hdl.handle.net/20.500.14414/20458
Olascuaga, K., Proteínas asociadas a vesículas extracelulares tumorales como biomarcadores potenciales en el diagnóstico, progresión y supervivencia en diferentes tipos de cáncer []. PE: Universidad Nacional de Trujillo; 2022. https://hdl.handle.net/20.500.14414/20458
@phdthesis{renati/1050905,
title = "Proteínas asociadas a vesículas extracelulares tumorales como biomarcadores potenciales en el diagnóstico, progresión y supervivencia en diferentes tipos de cáncer",
author = "Olascuaga Castillo, Karyn Alicia",
publisher = "Universidad Nacional de Trujillo",
year = "2022"
}
The research aimed to evaluate tumor extracellular vesicle-associated proteins as potential biomarkers in the diagnosis, progression and survival of different types of cancer. The primary proteomic data were obtained from open access TCGA databanks for 20 cancer types and HPA/GTEx for the counterpart in healthy individuals. The diagnostic value was obtained from 5895 samples from cancer patients and 626 samples from healthy individuals; the prognostic value was determined with data from 5494 surviving and 2202 deceased patients. The Q-Score of 06 proteins (CD9, PDCD6IP, HSPA8, ANXA2, ANXA5 and ANXA1) as diagnostic biomarkers was estimated, with ANXA1 expression being the most common up- and down-regulated (9 and 8 cancer types respectively). The highest unfavorable prognostic differential expressions were GAPDH in renal cancer; PGK1 in breast cancer and ENO1 in liver cancer. For the favorable prognostic proteins the best value were PDCD6IP in renal cancer; EEF2 in endometrial cancer and TUBB4B in thyroid cancer. The 5-year survival of patients who down-expressed unfavorable prognostic proteins were: 99% for CCT2 in prostate cancer; 97% for TFRC in thyroid cancer; 87% for PGK1 in breast cancer; 83% for YWHAZ in endometrial cancer; 81% for FLOT1 in colorectal cancer. The 5-year survival of patients who up-expressed favorable prognostic proteins were: 100% and 97% for ANXA1 and CD9 in thyroid cancer; 90% and 97% for TUBB4B in endometrial cancer and thyroid cancer; and 89% for GNAI2 in breast cancer.
This item is licensed under a Creative Commons License